Parexel International, a global biopharmaceutical services provider, has announced that its randomization and trial supply management (RTSM) services, ClinPhone RTSM, ranked as the leader of Interactive Response Technology (IRT), according to a new global survey of pharmaceutical and biotechnology companies by Industry Standard Research (ISR). ClinPhone RTSM also was cited as the most preferred and widely used IRT solution.

Parexel Informatics' ClinPhone RTSM service has been used in more than 3,200 studies involving more than 270,000 sites and 2.2 million patients since 1993. Additionally, ClinPhone RTSM has been used in more than 250 studies using covariate adaptive randomization techniques and 160 studies using adaptive trial designs. 

ClinPhone RTSM is a key component of the Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials. Parexel continues to strengthen its leadership position in RTSM. Through the recent acquisition and integration of ClinIntel, Parexel's next generation ClinPhone RTSM service offers clients an effective visual design approach that streamlines the system delivery process. Both ClinPhone RTSM and Perceptive MyTrials are available through the Perceptive Partner Program.

"ISR's report provides further endorsement of ClinPhone RTSM as the preferred provider and leader of IRT solutions worldwide," said Xavier Flinois, president of Parexel Informatics. "Randomization and trial supply management activities are critical to the success of our clients' clinical development journeys. Our ClinPhone RTSM services are agile, flexible and scalable, allowing us to address the complexity of different development phases, study types, geographic regions and client timelines."

In this report, 105 respondents rated 24 IRT vendors (including in-house systems) across 20 different system attributes based on user experience. Forty-eight percent of respondents rated Parexel ClinPhone RTSM as the leader in the IRT field.